SCHEMBL5491993

SCHEMBL5491993

Cc1ccc(NC(=O)c2cc(C(C)(C)C)nn2C)cc1-c1ccc2nc(N)ncc2c1

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LCK P06239 12/20 0.61
KDR P35968 9/20 0.61
JAK3 P52333 8/20 0.61
MAPK14 Q16539 8/20 0.61
TEK Q02763 3/20 0.61
BRAF P15056 4/20 0.50
DDR2 Q16832 1/20 0.48
INSR P06213 1/20 0.48
LYN P07948 1/20 0.48
HCK P08631 1/20 0.48
SRC P12931 1/20 0.48
AAK1 Q2M2I8 1/20 0.45
RAF1 P04049 2/20 0.43
ABL1 P00519 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5501170 0.83 LCK (0.74) LCKKDRJAK3MAPK14TEK
SCHEMBL5504079 0.82 LCK (0.73) LCKKDRJAK3MAPK14TEK
SCHEMBL5494016 0.80 LCK (0.78) LCKKDRJAK3MAPK14TEK
SCHEMBL14715547 0.80 LCK (0.68) LCKKDRJAK3MAPK14TEK
SCHEMBL5489194 0.80 LCK (0.60) LCKKDRJAK3MAPK14TEK
SCHEMBL5489144 0.79 LCK (0.67) LCKKDRJAK3MAPK14TEK
SCHEMBL5489006 0.79 LCK (0.67) LCKKDRJAK3MAPK14TEK
SCHEMBL5498227 0.79 LCK (0.55) LCKKDRJAK3MAPK14TEK
SCHEMBL2951675 0.78 LCK (0.57) LCKKDRMAPK14BRAFINSR
SCHEMBL5499129 0.78 LCK (0.76) LCKKDRJAK3MAPK14TEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP claimed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP claimed
EP-1836174-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC. (US) 2007-09-26 EP claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US claimed
WO-2006039718-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2006-04-13 WO claimed
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP disclosed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 LCK 106/4885KDR 1044/4885JAK3 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.